| Bioactivity | HDAC6-IN-22 (compound 30) is a inhibitor of HDAC6, with the IC50 of 4.63 nM. HDAC6-IN-22 has antiproliferative effects in vitro and in vivo towards multiple myeloma. HDAC6-IN-22induces cell cycle arrest in the G2 phase and promotes apoptosis through the mitochondrial pathway[1]. |
| Target | 4.63 nM (HDAC6) |
| Name | HDAC6-IN-22 |
| Formula | C24H24N4O2 |
| Molar Mass | 400.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu L, et al. Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma [published online ahead of print, 2023 Sep 25]. Eur J Med Chem. 2023;261:115833. |